Welcome to the eighth edition of Managing IP's India Focus. We have a diverse selection of articles this year that shows the wide range of issues facing India's IP system. These vary from questions over software patents and the patentability of pharmaceutical products to missing files at the trade mark office and accession to the Madrid Protocol. As this supplement goes to press, a key case dealing with the patentability of Novartis's anti-cancer drug Glivec is being argued at the Supreme Court. Patent practitioners are hoping the judgment may finally shed some light on the notorious Section 3(d) of the country's Patent Act. And in the Monsoon session of Parliament India's politicians may pass far-reaching amendments to the country's Copyright Act.
